Journals / Türk Nöroloji Dergisi / 2021 / Cilt: 27 - Sayı: 3

Clinical Outcomes of Thrombolytic Therapy in Patients with Mild Stroke: A Single-center Experience in a Tertiary Care Institution

Hafif İnmeli Hastalarda Trombolitik Tedavinin Klinik Sonuçları: Üçüncü Basamak Sağlık Kurumunda Tek Merkez Deneyimi

Pages
301–305
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This study highlights the efficacy of iv-tPA in patients with acute ischemic stroke and mild symptoms and demonstrates the low-risk profile of this therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Mild stroke is used to describe patients with stroke having a National Institutes of Health Stroke Scale (NIHSS) score of 0-6.
📊
Key Findings & Data:This study aimed to analyze data of patients who applied to our stroke center with an acute mild stroke clinic and received iv-tPA treatment and 3-month follow-up.
💡
Conclusion & Impact:Conclusion: This study highlights the efficacy of iv-tPA in patients with acute ischemic stroke and mild symptoms and demonstrates the low-risk profile of this therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Mild stroke is used to describe patients with stroke having a National Institutes of Health Stroke Scale (NIHSS) score of 0-6. However, there is still no clear decision regarding the application of intravenous (iv) recombinant tissue plasminogen activator (iv-tPA) to patients who were admitted with an acute ischemic stroke and were in the mild stroke category. This study aimed to analyze data of patients who applied to our stroke center with an acute mild stroke clinic and received iv-tPA treatment and 3-month follow-up. Materials and Methods: Of 350 patients receiving thrombolytic therapy, 47 (age 69.1±14.1, 28 female) patients with mild stroke were included. iv thrombolysis was initiated with a maximum delay of 4.5 h in all patients. Patients had an NIHSS score of less than 6. NIHSS scores immediately before starting thrombolytic therapy and scores 24 h after treatment were recorded. Modified rankin scale scores (mRS) at admission and at 1 and 3 months were recorded. Results: The NIHSS scores of patients who received tPA decreased significantly after the treatment (p=0.001). The mRS scores of the patients at the first and third months were significantly decreased according to the mRS scores when they entered the treatment (p=0.001). Conclusion: This study highlights the efficacy of iv-tPA in patients with acute ischemic stroke and mild symptoms and demonstrates the low-risk profile of this therapy.

Özet

Amaç: “Hafif inme” deyimi Ulusal Sağlık Enstitüleri İnme Ölçeği (NIHSS) skoru 0-6 arasında olan hastaları belirtmek için kullanılmaktadır. Akut iskemik inme ile başvuran ve hafif inme kategorisinde olan hastalara intravenöz (iv) rekombinant doku plazminojen aktivatörünün (iv-tPA) uygulanmasına ilişkin hala net bir karar yoktur. Çalışmamızda akut hafif inme kliniği ile inme merkezimize başvuran ve iv-tPA tedavisi alan hastaların verilerini ve üç aylık takiplerini incelemeyi amaçladık. Gereç ve Yöntem: Trombolitik tedavi alan 350 hastadan 47 (yaş; 69,1±14,1, 28 kadın) hafif inme hastası çalışmaya dahil edildi. Tüm hastalara maksimum 4,5 saat gecikmeyle iv tromboliz başlandı. Hastaların NIHSS skoru 6’dan düşüktü. Trombolitik tedaviye başlamadan hemen önceki NIHSS skorları ve tedaviden 24 saat sonraki skorlar kaydedildi. Başvuruda, 1. ve 3. aylarda modifiye rankin skoru puanları (mRS) kaydedildi. Bulgular: Tedavi sonrası tPA alan hastaların NIHSS skorlarının anlamlı şekilde azaldığı görüldü (p=0,001). Hastaların 1. ve 3. ay mRS skorları tedaviye başladıklarındaki mRS skorlarına göre istatistiksel olarak anlamlı azaldığı izlendi (p=0,001). Sonuç: Bu çalışmadaki veriler hafif inme grubundaki akut iskemik serebrovasküler olay geçiren hastalarda verilen iv-tPA tedavisinin etkinliğini, uzun dönem engelliliği önemli ölçüde azalttığını göstermektedir.

🔖

Cite This Article

KARADELİ, H. H., ŞİMŞEKOĞLU, R. (2022). Clinical Outcomes of Thrombolytic Therapy in Patients with Mild Stroke: A Single-center Experience in a Tertiary Care Institution. Türk Nöroloji Dergisi, Cilt: 27 - Sayı: 3, 301–305. https://ajindex.com/articles/636554

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Del Zoppo GJ, Saver JL, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945-2948
  2. Dhamoon MS, Moon YP, Paik MC, et al. Long-term functional recovery after first ischemic stroke: The Northern Manhattan Study. Stroke 2009;40:2805-2811
  3. Chandratheva A, Geraghty OC, Rothwell PM, Poor performance of current prognostic scores for early risk of recurrence after minor stroke. Stroke 2011;42:632-637
  4. Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis a er emergency department diagnosis of TIA. JAMA 2000;284:2901-2906
  5. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587
  6. Cocho D, Belvís R, Martí-Fàbregas J, et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005;64:719-720
  7. Khatri P, Kleindorfer DO, Devlin T, et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: The PRISMS randomized clinical trial. JAMA 2018;10;320:156-166
  8. Powers WJ, Rubinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2019;50:344-418
  9. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870
  10. Muir KW, Weir CJ, Murray GD, et al. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke 1996;27:1817-1820
  11. Williams LS, Yilmaz EY, Lopez-Yunez AM. Retrospective assessment of initial stroke severity with the NIH Stroke Scale. Stroke 2000;31:858-862
  12. Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020
  13. Cheng NT, Kim AS. Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom Onset. Neurohospitalist 2015;5:101-109
  14. Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators